Apokyn (apomorphine)

Apokyn (apomorphine) is covered for up to 12 months for the acute, intermittent treatment of hypomobility "off" episodes in advanced Parkinson’s disease (subcutaneous only) and is not covered for non‑FDA or chronic continuous indications. Key requirements: patient must be on carbidopa/levodopa, have documented significant intolerance or inadequate response to at least one other "off" therapy, be prescribed by or in consultation with a neurologist, and follow recommended dosing/titration (start 1–2 mg, max 6 mg).

"Apokyn (apomorphine) is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Park..."

Sign up to see full coverage criteria, indications, and limitations.